CLEVERCARDS
8.7.2021 17:32:08 CEST | Business Wire | Press release
Giuseppe Di Marco has joined CleverCards as Senior Vice President for Business Development Europe & Managing Director of CleverCards Italia, from Accel and Battery Ventures-backed, mid-market Spend Management leader, Soldo.
Di Marco led and built the Soldo business in Italy after a successful payments career as CEO of ePay Italy (Euronet: EEFT), CEO of the Zucchetti eCommerce and payments services division (Zucchetti is Italian market leader of ERP and HR software), Managing Director of Lottomatica Payments Services Division (LIS & Totobit Servizi) and Head of QuiGroup Payments Service Division.
CleverCards is a leading global payments platform which makes it possible for anyone, anywhere, anytime, to be paid instantly by enabling businesses, governments and public sector organisations to simply send a digital prepaid Mastercard to an email address or mobile phone number by SMS or WhatsApp, empowering the recipients to spend online, or use their mobile in-store contactlessly using Google Pay, Samsung Pay or Apple Pay immediately.
“The US and European B2B payment markets are highly fragmented and CleverCards is planning to consolidate it through an aggressive buy and build acquisition strategy, driving growth and expansion through digital transformation realising its vision of becoming the ubiquitous global payments platform”, says Kealan Lennon, Founder & CEO of CleverCards.
Earlier this year, CleverCards entered into a definitive agreement to acquire ExpendiaSmart®, a market leader in Europe for Spend Management Solutions and Smart Corporate Cards, along with a Licensed, Electronic Money Institution, subject to regulatory approval.
In February this year, Mastercard and CleverCards signed a strategic partnership and development agreement to expand the usage of digital cards across Europe, a FinTech partnership that provides unprecedented, unique access to Mastercard business development teams in key markets and to key commercial clients.
“Our B2B payments platform is growing exponentially, as organisations seek to manage employee, vendor and customer pay-outs on one platform. CleverCards needed someone with an intimate understanding of the payments industry and a demonstrable ability to rapidly scale a Fintech business. In Giuseppe we’ve found that. His track record speaks for itself and we’re very excited about CleverCards continued European expansion,” adds Lennon.
At CleverCards, Giuseppe will build upon the company’s reputation as a market leader in the corporate sector with Spend Management Solutions and Smart Corporate Cards for employees, drivers and contractors, into the Public Sector with digital Mastercards, empowering social welfare recipients to spend online, or use their mobile in-store contactlessly using Google Pay, Samsung Pay or Apple Pay.
Di Marco comments, “The future of payments is digital. While many companies are scrambling to offer individual B2B solutions, none enable large private or public sector organisations to manage employee, vendor, customer or public sector payments on one platform like CleverCards. We’re providing organisations with greater speed, control and flexibility on pay-outs than ever before. I think that’s a really exciting proposition and both organisations and cardholders love it!”
ENDS
ABOUT CLEVERCARDS
Public and private sector organisations of all sizes use the CleverCards payments platform, making it possible for anyone, anywhere, anytime to be paid instantly, regardless of where they are and without the need for a bank account. Empowered with effortless configuration, customised branding and personalisation, along with elegant mobile-first cardholder experiences, CleverCards uses technology to remove numerous unnecessary processes and participants from the payments value chain, delivering unrivalled efficiencies whilst automating the management of all relevant financial services regulations, including KYC and KYB onboarding, AML and PCI DSS compliance. Since launching its payments platform in December 2019, CleverCards has experienced dramatic growth, with over 5,000 large enterprise businesses and public sector organisations already using the platform. For more information visit www.clevercards.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005694/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom